Dilantin and Dermatitis - atopic - a phase IV clinical study of FDA data

Summary:

Dermatitis - atopic is reported as a side effect among people who take Dilantin (phenytoin sodium), especially for people who are male, 40-49 old, also take Tylenol, and have Convulsion.

The phase IV clinical study analyzes which people have Dermatitis - atopic when taking Dilantin. It is created by eHealthMe based on reports of 19,857 people who have side effects when taking Dilantin from the FDA, and is updated regularly.

What is Dilantin?

Dilantin has active ingredients of phenytoin sodium. It is often used in epilepsy. eHealthMe is studying from 20,858 Dilantin users. Check the latest studies of Dilantin.

What is Dermatitis - atopic?

Dermatitis - atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder) is found to be associated with 2,004 drugs and 1,973 conditions by eHealthMe. Check the latest studies of Dermatitis - atopic.

On Jul, 09, 2026

19,857 people reported to have side effects when taking Dilantin.
Among them, 13 people (0.07%) have Dermatitis - atopic.

Could Dilantin cause Dermatitis - atopic?

Among these 13 people:

What is the gender of people who have Dermatitis - atopic when taking Dilantin? *

female: 38.46 %
male: 61.54 %

What is the age of people who have Dermatitis - atopic when taking Dilantin? *

What are other drugs people take besides Dilantin? *

Zoloft: 2 people, 15.38%
Triamcinolone Acetonide: 2 people, 15.38%
Alendronate Sodium: 2 people, 15.38%
Ibuprofen: 2 people, 15.38%
Keppra: 2 people, 15.38%
Metformin: 2 people, 15.38%
Prilosec: 2 people, 15.38%
Lorazepam: 2 people, 15.38%
Tylenol: 2 people, 15.38%
Triamcinolone: 1 person, 7.69%

What are other side effects people have besides Dermatitis - atopic? *

Itching: 5 people, 38.46%
Headache (pain in head): 4 people, 30.77%
Psoriasis (immune-mediated disease that affects the skin): 3 people, 23.08%
Stress And Anxiety: 3 people, 23.08%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 3 people, 23.08%
Rashes (redness): 3 people, 23.08%
Rash Maculo-Papular (red area on the skin that is covered with small confluent bumps): 2 people, 15.38%
Skin Atrophy (wasting of skin): 2 people, 15.38%
Drug Ineffective: 2 people, 15.38%
Drug Hypersensitivity: 2 people, 15.38%

What are the existing conditions these people have? *

Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 4 people, 30.77%
Pain: 2 people, 15.38%
Osteoporosis (bones weak and more likely to break): 2 people, 15.38%
Type 2 Diabetes: 1 person, 7.69%
Seasonal Allergy (allergic condition due to certain season): 1 person, 7.69%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 7.69%
Osteoporosis Post-Menopausal (weak bone with possibility to break after stopped menstrual cycles): 1 person, 7.69%
Insomnia (sleeplessness): 1 person, 7.69%
High Blood Pressure: 1 person, 7.69%
Headache (pain in head): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Dilantin and have Dermatitis - atopic?

- Check whether Dermatitis - atopic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dilantin:

Dilantin (20,858 reports)

Browse all side effects of Dilantin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatitis - atopic:

Dermatitis - atopic (2,004 drugs)

Browse all the conditions that are associated with Dermatitis - atopic:

Dermatitis - atopic (1,973 conditions)

Related publications that referenced our studies

Akasaka E, Kayo SJ, Nakano H, Ishii N, Hashimoto T, Sawamura D, "Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis", Case reports in dermatology, 2014 Jan .
Akasaka E, Kayo SJ, Nakano H, Ishii N, Hashimoto T, Sawamura D, "Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis", Case reports in dermatology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on phenytoin sodium (the active ingredients of Dilantin) and Dilantin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.